Changchun BCHT Biotechnology Co. Class A

As of June 30, 2026, Changchun BCHT Biotechnology Co. Class A carries a market capitalization of 5.77B, placing it among publicly traded companies globally. Its enterprise value stands at 5.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Changchun BCHT Biotechnology Co. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Changchun BCHT Biotechnology Co. Class A has 413.66M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.92, and the price-to-book ratio stands at 1.52.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.95B versus a market cap of 5.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Changchun BCHT Biotechnology Co. Class A maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.45, indicating elevated leverage, while an interest coverage ratio of -49.76 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Changchun BCHT Biotechnology Co. Class A posted a negative return on equity (ROE) of -5.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.41, reflecting losses generated across the asset base. The company generates approximately 443,539.93 in revenue per employee across its workforce of 1,257.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.54 indicates how many times Changchun BCHT Biotechnology Co. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Changchun BCHT Biotechnology Co. Class A recorded an income tax benefit of -56.95M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -288.02M and -231.07M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Changchun BCHT Biotechnology Co. Class A's stock has declined approximately 28.33% over the past 52 weeks. The 50-day moving average sits at 16.53, while the 200-day moving average is 17.20.

Over the twelve months ended June 30, 2026, Changchun BCHT Biotechnology Co. Class A generated 557.75M in revenue and converted that into -231.07M in net income, yielding earnings per share of -0.58. EBITDA reached -269.66M, while operating income came in at -197.11M.

As of June 30, 2026, Changchun BCHT Biotechnology Co. Class A holds 284.60M in cash and equivalents against 472.43M in total debt, resulting in a net debt position of 135.94M. Total book value stands at 3.79B, with working capital of 304.31M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Changchun BCHT Biotechnology Co. Class A posted a gross margin of 73.56, reflecting its pricing power and cost economics. The operating margin of -35.34 and net profit margin of -41.43 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Changchun BCHT Biotechnology Co. Class A paid dividends of 0.19 per share. The dividend payout ratio of -33.13 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.26, meaning Changchun BCHT Biotechnology Co. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Changchun BCHT Biotechnology Co. Class A has an Altman Z-Score of 2.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.